103 related articles for article (PubMed ID: 21177056)
1. Interplay between p53-family, their regulators, and PARPs in DNA repair.
Emami S
Clin Res Hepatol Gastroenterol; 2011 Feb; 35(2):98-104. PubMed ID: 21177056
[TBL] [Abstract][Full Text] [Related]
2. The deubiquitinating enzyme USP24 is a regulator of the UV damage response.
Zhang L; Nemzow L; Chen H; Lubin A; Rong X; Sun Z; Harris TK; Gong F
Cell Rep; 2015 Jan; 10(2):140-7. PubMed ID: 25578727
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation.
Kanai M; Hanashiro K; Kim SH; Hanai S; Boulares AH; Miwa M; Fukasawa K
Nat Cell Biol; 2007 Oct; 9(10):1175-83. PubMed ID: 17891139
[TBL] [Abstract][Full Text] [Related]
4. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy.
Birks EJ; Latif N; Enesa K; Folkvang T; Luong le A; Sarathchandra P; Khan M; Ovaa H; Terracciano CM; Barton PJ; Yacoub MH; Evans PC
Cardiovasc Res; 2008 Aug; 79(3):472-80. PubMed ID: 18375498
[TBL] [Abstract][Full Text] [Related]
5. The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage.
van der Watt PJ; Leaner VD
Biochim Biophys Acta; 2011 Jul; 1809(7):316-26. PubMed ID: 21683812
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the p53/MDM2 interplay by HAUSP inhibitors.
Tavana O; Gu W
J Mol Cell Biol; 2017 Feb; 9(1):45-52. PubMed ID: 27927749
[TBL] [Abstract][Full Text] [Related]
7. Roles for negative cell regulator 14-3-3sigma in control of MDM2 activities.
Yang HY; Wen YY; Lin YI; Pham L; Su CH; Yang H; Chen J; Lee MH
Oncogene; 2007 Nov; 26(52):7355-62. PubMed ID: 17546054
[TBL] [Abstract][Full Text] [Related]
8. USP10 regulates p53 localization and stability by deubiquitinating p53.
Yuan J; Luo K; Zhang L; Cheville JC; Lou Z
Cell; 2010 Feb; 140(3):384-96. PubMed ID: 20096447
[TBL] [Abstract][Full Text] [Related]
9. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
[TBL] [Abstract][Full Text] [Related]
10. Subcellular Distribution of p53 by the p53-Responsive lncRNA
Mitra S; Muralidharan SV; Di Marco M; Juvvuna PK; Kosalai ST; Reischl S; Jachimowicz D; Subhash S; Raimondi I; Kurian L; Huarte M; Kogner P; Fischer M; Johnsen JI; Mondal T; Kanduri C
Cancer Res; 2021 Mar; 81(6):1457-1471. PubMed ID: 33372039
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage.
Cai X; Liu X
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):16958-63. PubMed ID: 18952844
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation.
Wang X; Ohnishi K; Takahashi A; Ohnishi T
Oncogene; 1998 Dec; 17(22):2819-25. PubMed ID: 9879988
[TBL] [Abstract][Full Text] [Related]
13. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
15. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.
Okamoto K; Kashima K; Pereg Y; Ishida M; Yamazaki S; Nota A; Teunisse A; Migliorini D; Kitabayashi I; Marine JC; Prives C; Shiloh Y; Jochemsen AG; Taya Y
Mol Cell Biol; 2005 Nov; 25(21):9608-20. PubMed ID: 16227609
[TBL] [Abstract][Full Text] [Related]
16. [Progress of p53 gene].
Xu SF; Fu L
Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):559-61. PubMed ID: 15634457
[No Abstract] [Full Text] [Related]
17. Role of Mdm2 and Mdmx in DNA repair.
Eischen CM
J Mol Cell Biol; 2017 Feb; 9(1):69-73. PubMed ID: 27932484
[TBL] [Abstract][Full Text] [Related]
18. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.
Wasylishen AR; Lozano G
Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27329033
[TBL] [Abstract][Full Text] [Related]
19. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.
Nabha SM; Mohammad RM; Dandashi MH; Coupaye-Gerard B; Aboukameel A; Pettit GR; Al-Katib AM
Clin Cancer Res; 2002 Aug; 8(8):2735-41. PubMed ID: 12171907
[TBL] [Abstract][Full Text] [Related]
20. The p53 mutation "gradient effect" and its clinical implications.
Zambetti GP
J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
